Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review

Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Revance Therapeutics Inc (Revance Therapeutics) is a biotechnology company that focuses on the development, manufacturing and marketing novel botulinum toxin products. Its approved products are daxibotulinumtoxinA-lanm injection (DAXI) for two conditions cervical dystonia and glabellar (frown) lines. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.

Revance Therapeutics Inc Key Recent Developments

Nov 08,2023: Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
Sep 19,2023: Revance Provides Corporate Update at Investor Day
Jan 09,2023: Revance Provides an Update on preliminary fourth quarter and full year 2022 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Revance Therapeutics Inc - Key Facts
Revance Therapeutics Inc - Key Employees
Revance Therapeutics Inc - Key Employee Biographies
Revance Therapeutics Inc - Major Products and Services
Revance Therapeutics Inc - History
Revance Therapeutics Inc - Company Statement
Revance Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Revance Therapeutics Inc - Business Description
Business Segment: Product
Overview
Performance
Business Segment: Service
Overview
Performance
R&D Overview
Revance Therapeutics Inc - Corporate Strategy
Revance Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Revance Therapeutics Inc - Strengths
Revance Therapeutics Inc - Weaknesses
Revance Therapeutics Inc - Opportunities
Revance Therapeutics Inc - Threats
Revance Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Revance Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 08, 2023: Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
Sep 19, 2023: Revance Provides Corporate Update at Investor Day
Jan 09, 2023: Revance Provides an Update on preliminary fourth quarter and full year 2022 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Revance Therapeutics Inc, Key Facts
Revance Therapeutics Inc, Key Employees
Revance Therapeutics Inc, Key Employee Biographies
Revance Therapeutics Inc, Major Products and Services
Revance Therapeutics Inc, History
Revance Therapeutics Inc, Subsidiaries
Revance Therapeutics Inc, Key Competitors
Revance Therapeutics Inc, Ratios based on current share price
Revance Therapeutics Inc, Annual Ratios
Revance Therapeutics Inc, Annual Ratios (Cont...1)
Revance Therapeutics Inc, Annual Ratios (Cont...2)
Revance Therapeutics Inc, Interim Ratios
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Revance Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Revance Therapeutics Inc, Performance Chart (2019 - 2023)
Revance Therapeutics Inc, Ratio Charts
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings